Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Cash from Operations (2020 - 2025)

SAB Biotherapeutics' Cash from Operations history spans 6 years, with the latest figure at 16776327.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 76.0% year-over-year to 16776327.0; the TTM value through Dec 2025 reached 44775111.0, down 30.57%, while the annual FY2025 figure was 44775111.0, 30.57% down from the prior year.
  • Cash from Operations reached 16776327.0 in Q4 2025 per SABSW's latest filing, down from 13050023.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 9453495.0 in Q1 2021 to a low of 16776327.0 in Q4 2025.
  • Average Cash from Operations over 5 years is 6282958.15, with a median of 6768720.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: tumbled 48526.09% in 2021, then skyrocketed 83.16% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 4878169.0 in 2021, then surged by 68.12% to 1555024.0 in 2022, then tumbled by 764.73% to 13446717.0 in 2023, then grew by 29.11% to 9532188.0 in 2024, then plummeted by 76.0% to 16776327.0 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Cash from Operations are 16776327.0 (Q4 2025), 13050023.0 (Q3 2025), and 7151544.0 (Q2 2025).